MDK(SH:688079)2023-04-27 16:00Financial Performance - The company's operating revenue for Q1 2023 was ¥94,743,858.55, representing a decrease of 10.91% compared to the same period last year[5]. - The net profit attributable to shareholders was -¥5,176,573.18, a decline of 134.77% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses decreased by 141.73% compared to the previous year[10]. - Basic and diluted earnings per share were both -¥0.01, reflecting a decrease of 125.00%[6]. - The company reported a gross loss of ¥6,019,384.87 for Q1 2023, compared to a gross profit of ¥12,806,477.61 in Q1 2022[22]. Assets and Liabilities - The total assets at the end of the reporting period were ¥2,054,372,230.97, an increase of 7.61% from the end of the previous year[6]. - As of March 31, 2023, the company's total assets reached CNY 2,054,372,230.97, an increase from CNY 1,909,069,716.52 as of December 31, 2022, reflecting a growth of approximately 7.6%[16]. - The total liabilities increased to ¥466,641,836.26, up from ¥316,517,031.66, representing a growth of 47.4%[19]. - The company reported a total current liabilities of CNY 527,356,674.37, compared to CNY 470,375,325.91, indicating an increase of approximately 12.1%[17]. - The total equity attributable to shareholders decreased to ¥1,544,878,159.50 from ¥1,549,634,262.25, a decline of 0.3%[19]. Cash Flow - Cash flow from operating activities was ¥49,264,932.46, down by 17.79% year-on-year[6]. - In Q1 2023, the company's operating cash inflow totaled ¥183,340,098.55, a decrease of 17.9% from ¥223,239,624.59 in Q1 2022[25]. - The net cash flow from operating activities was ¥49,264,932.46, down 17.7% compared to ¥59,923,586.91 in the same period last year[25]. - Cash inflow from financing activities was ¥131,000,000.00, significantly higher than ¥58,575,268.15 in the previous year, marking an increase of 123.2%[26]. - The company received ¥18,829,166.29 in tax refunds, a decrease of 37.0% from ¥29,858,122.86 in Q1 2022[25]. Research and Development - Research and development expenses totaled ¥17,294,513.08, which is an increase of 22.77% year-on-year[6]. - R&D expenses accounted for 18.25% of operating revenue, up by 5.00 percentage points compared to the previous year[6]. - Research and development expenses rose to ¥17,294,513.08, an increase of 22.5% from ¥14,086,515.22 in the previous year[21]. Operational Challenges - The company faced increased costs in fixed asset depreciation, labor, and utilities, contributing to the decline in net profit[10]. - The company's cash and cash equivalents amounted to CNY 386,094,155.38, up from CNY 334,790,386.18, indicating an increase of about 15.3%[16]. - Accounts receivable increased to CNY 40,108,354.33 from CNY 30,205,082.51, representing a growth of approximately 32.8%[16]. - Inventory decreased to CNY 63,162,472.14 from CNY 68,481,598.53, showing a decline of about 7.5%[17]. - The company did not report any cash inflow from recovering investments, contrasting with ¥202,672,908.63 in Q1 2022[25]. Other Information - The company has not disclosed any new product developments or market expansion strategies in the provided content[15]. - There are no significant mergers or acquisitions mentioned in the current report[15]. - The financial expenses decreased significantly to ¥3,955,314.28 from ¥11,841,667.82, a reduction of 66.6%[22]. - The company's non-current assets totaled CNY 1,527,015,556.60, up from CNY 1,438,694,390.61, marking an increase of approximately 6.2%[17]. - Short-term borrowings rose significantly to CNY 208,381,383.10 from CNY 106,881,135.70, reflecting an increase of about 95%[17].